KAUST researchers have developed a new synthetic biology process using metabolically engineered algae to produce fragrant sesquiterpenoids, the core compounds in agarwood and other perfumes. The process, developed by the Lauersen and Szekely groups, achieved yields 25 times higher than previous methods and allows for the synthesis of 103 types of fragrant sesquiterpenoids. It also incorporates an energy-efficient nanofiltration step and operates at room temperature with minimal waste. Why it matters: This sustainable bioprocess offers a green alternative to environmentally damaging harvesting of natural resources for the $44 billion fragrance industry, with potential applications in drug development.
MBZUAI and GenBio AI have won the UAE AI Award 2025 in the AI Scientific Research category for their "Unified Protein Language Modeling Framework". The winning project enables AI to learn protein function, generate sequences, and predict 3D structures. The AI-driven simulation approach aims to accelerate drug development, reduce costs, and improve success rates. Why it matters: This award highlights the UAE's commitment to fostering AI innovation in biomedicine and drug discovery, positioning the region as a leader in AI-driven healthcare advancements.
MBZUAI and Quris-AI have partnered to launch a Bio-AI center in Abu Dhabi during Abu Dhabi Sustainability Week. The center will focus on developing personalized medications tailored to the MENA region's diverse populations, leveraging Quris-AI's 'patient-on-a-chip' technology and MBZUAI's AI expertise. Quris-AI is establishing a UAE subsidiary, Quris-UAE, in Abu Dhabi as part of this collaboration. Why it matters: This initiative positions Abu Dhabi as a hub for Bio-AI research and personalized medicine, potentially accelerating drug development and reducing clinical trial failures in the region.
Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.
A KAUST alumnus presented research on using large language models for complex disease modeling and drug discovery. LLMs were trained on insurance claims of 123 million US people to model diseases and predict genetic parameters. Protein language models were developed to discover remote homologs and functional biomolecules, while RNA language models were used for RNA structure prediction and reverse design. Why it matters: This work highlights the potential of LLMs to accelerate computational biology research and drug development, with a KAUST connection.
MBZUAI's Kun Zhang is applying causal machine learning to improve drug development and precision medicine, focusing on answering 'why' questions. Traditional drug development is costly (est. $2B) due to extensive studies needed to determine drug toxicity and efficacy. Zhang is combining causal ML with organs-on-chips technology to improve pre-clinical drug testing, aiming to reduce the failure rate of drugs in human trials. Why it matters: By improving the accuracy of pre-clinical drug testing, this research could significantly reduce the cost and time required to bring new medicines to market in the region and worldwide.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.